Gail Boudreaux, President and CEO at Elevance Health, Inc. (ELV), bought 2,725 shares at $366.41 ($1.0M) on 2026-07-17, disclosed to the SEC on 2026-07-17.
CEO Gail Boudreaux purchased 680 shares for $249k on July 17, 2026, signaling confidence in the stock despite a 6.44% pullback over the past five days. This move follows the company's Q2 earnings beat and guidance raise, though the stock remains 10.17% below its 52-week high of $433.64.
ELV has dropped 6.44% over the last five days to $389.52, though it remains 20.58% higher over the past 90 days and 42.31% above its 52-week low of $273.71.
Catalysts include the Q2 earnings beat and guidance raise reported on July 16, 2026, and Bernstein SocGen lifting the price target to $482 on July 16, 2026.
Risks include the 'Medicaid Problem' weighing on the stock as noted in recent reports on July 16, 2026, and the 3.1% short interest on the float.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $366.41 | 680 | $249K | 24.9% |
| 2 | $368.25 | 2,045 | $753K | 75.1% |
| Total | $367.79 avg | 2,725 | $1.0M | 100% |
| Filing → |
| ANTM | BUY | 2020-01-31 | $2.0M | — | Filing → |
| ZBH | BUY | 2019-02-06 | $500K | — | Filing → |
| NVAX | BUY | 2016-09-21 | $145K | — | Filing → |